Wingsar Indrawanto, adi koesoema Aman, Alwi Thamrin


Background : End stage renal disease patients who undergo hemodialysis therapy are the high-risk populations who are infected by hepatitis C virus. Some studies have been reported that hepcidin levels decreased in patients with chronic hepatitis C. Hepcidin serum concentrations were also reported to increase in patients with renal failure in the line with increased severity of renal failure, which can cause the accumulation of hepcidin which culminates in anemia because iron deficiency. This Study was to analyze the correlation of anemia and hepcidin serum levels in patients end stage renal disease who undergoing regular hemodialysis with chronic hepatitis C.

Methods : This study was an analytic observational with cross sectional design which was conduted on 24 patients end stage renal disease (ESRD) with chronic hepatitis C and 24 patients  with ESRD without hepatitis who are undergoing regular hemodialysis theraphy in Haji Adam Malik Hospital, Medan in July – September 2016. All study subjects were examined for full blood count and hepcidin serum levels. The result of the iron status were recorded from the patient’s medical record.

Result : In this study, the mean hemoglobin was 8,15±1,44 g/dL, mean hematocrit 25,42±4,53%, median hepcidin levels 29,75 (4,92-359,49) in the patients ESRD with chronic hepatitis C  and mean hemoglobin 8,21±1,50 g/dL, mean hematocrit 25,25±4,37%, median hepcidin levels 30,33 (11,65-141,53) in the patients ESRD without hepatitis. In Spearman’s rho test  was showed a positive correlation that significant between hepcidin and hemoglobin (r = 0,439, p = 0,032), hepcidin and hematocrit (r = 0,021, p = 0,024) in patients ESRD with chronic hepatitis C.

Conclusion : This study showed there was a positive correlation between anemia and hepcidin serum levels in patients ESRD who undergoing regular hemodialysis with chronic hepatitis C.


: End stage renal disease, anemia, hemodialysis, hepatitis C, non hepatitis, hepcidin

Full Text:



K/DOQI.National Kidney F. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2006 ; 47(5 Suppl 3):S11-145.

Robinson BE. Epidemiology of chronic kidney disease and anemia. Journal of the American Medical Directors Association. 2006 ; 7(9 Suppl):S3-6; quiz S17-21.

Denny SD, Kuchibhatla MN, Cohen HJ. Impact of anemia on mortality, cognition, and function in community-dwelling elderly. The American journal of medicine. 2006;119(4):327-334.

Ismatullah A. Manajemen terapi Anemia pada Pasien Gagal Ginjal Kronik. (Mei 19. 2016).

United States Renal Data System (USRDS). 2011. Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2011.

Perhimpunan Nefrologi Indonesia (PERNEFRI). 4th Annual Report of Indonesian Renal Registry. 2011.

Suwitra K. Penyakit Ginjal Kronik. In Sudoyo AW, Setiyohadi B, Alwi I, et al., (Eds). Buku Ajar Ilmu Penyakit Dalam. Jakarta: InternaPublishing 2009:1035-1040.

National Kidney Foundation. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification and stratification. Am J Kidney Dis 39: suppl 1, 2002.

Rachmiwatie A, Noormartany RS, Gondodiputro, dan D Prihatni, 2013i ; Kadar Hemoglobin retikulosit di anemia dan non anemia akibat defisiensi besi absolut di gagal ginjal terminal terkait hemodialisa. Indnesia journal of clinical pathology and medical laboratory. 2(1):32-39.

Jonckheere SJ, Dierick H, Vanhauteghem M, Delveeschouwer and stove V, 2010; Erytrocyte indices in the assessment of iron status in dialysis dependent patients with end stage renal disease on continuous erythropoietin receptor activator versus epoetin therapy. Acta Haematol, 124:21-33.

Ibrahim K, Taboonpong S, Nilmanat K. Coping and Quality of life among Indonesians Undergoing Hemodialysis. Thai J Nurs Res. 2009 ; 13(2):117-109.

Natov SN, Pereira BJ. Hepatitis C in dialysis patients. Adv Ren Replace Ther. 1996;3(4):275-83.

Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther. 2004;20:1271-7.

DeDomenico I, McVey Ward D, Kaplan J. Regulation of iron acquisition and storage: consequences for iron-linked disorders. Nat Rev Mol Cell Biol. 2008;9:72–81.

Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM

et al. Hepcidin regulates cellular iron efflux by binding to feroportin and inducing its internalization. Science. 2004;306:2090-3.

Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood. 2003;102:783–788.

Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004;117:285–297.

Fujita N, Sugimoto R, Takeo M, et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med. 2007 Jan-Feb; 13(1-2): 97–104.

Girelli D, Pasino M, Goodnough JB et al. Reduced serum hepcidin levels in patients with chronic hepatitis c. J of Hepatol 2009 ; 51: 845-852.

Khadr et al., Afro-Egypt J Infect Endem Dis 2014; 4(4): 184-194.

Alsaran KA, Sabry AA, Alghareeb AH, Al Sadoon G. Effect of hepatitis C virus on hemoglobin and hematocrit levels in Saudi hemodialysis patients. Ren Fail 2009;31:349-54.

Altintepe L, Kurtoglu E, Tonbul Z, Yeksan M, Yildiz A, Turk S. Lower erythropoietin and iron supplementation are required in hemodialysis patients with hepatitis C virus infection. Clin Nephrol.2004;6:347-51.

Lin YL, Lin CW, Lee CH, Lai IC, Chen HH, Chen TW. Chronic hepatitis ameliorates anaemia in hemodialysis patients. Nephrology (Carlton) 2008;13:289-93.

Khurana A, Nickel AE, Narayanan M, Foulks CJ. Effect of hepatitis C infection on anemia in hemodialysis patients. Hemodial Int 2008;12:94-9.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.